The CYP2D6 enzyme is involved in the metabolism of many commonly prescribed drugs. The presence of CYP2D6 gene SNPs can alter CYP2D6 enzymatic activity with effects ranging considerably within a population. Objectives: In this study we have developed a genotyping platform able to determine the alleles related to interindividual variability in CYP2D6 gene. Design and methods: We used a Long PCR strategy coupled to MALDI–TOF mass spectrometry (Sequenom®) to develop a SNPs genotyping method. Furthermore, an amplification allele–specific was carried out to infer the correct allelic phase. Results: We tested the multiplex platform in 250 DNA Sardinian samples and found it to be 100% concordant with the sequencing results of our previous work. Conclusions: The MALDI–TOF–based multiplexing system allowed simultaneous and efficient genotyping of a set of CYP2D6 SNPs, evidencing its potential use in diagnostic test development to predict drug responses and clinical outcomes

Genotyping of CYP2D6 polymorphisms by MALDI–TOF mass spectrometry in Sardinian people

FALZOI, MATTEO;
2013-01-01

Abstract

The CYP2D6 enzyme is involved in the metabolism of many commonly prescribed drugs. The presence of CYP2D6 gene SNPs can alter CYP2D6 enzymatic activity with effects ranging considerably within a population. Objectives: In this study we have developed a genotyping platform able to determine the alleles related to interindividual variability in CYP2D6 gene. Design and methods: We used a Long PCR strategy coupled to MALDI–TOF mass spectrometry (Sequenom®) to develop a SNPs genotyping method. Furthermore, an amplification allele–specific was carried out to infer the correct allelic phase. Results: We tested the multiplex platform in 250 DNA Sardinian samples and found it to be 100% concordant with the sequencing results of our previous work. Conclusions: The MALDI–TOF–based multiplexing system allowed simultaneous and efficient genotyping of a set of CYP2D6 SNPs, evidencing its potential use in diagnostic test development to predict drug responses and clinical outcomes
2013
CYP2D6; individualized therapy; MALDI-TOF mass spectrometry; genotyping; Sardinians
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/62881
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact